Baird maintains Axsome Therapeutics at Outperform, lowers price target to $220 from $246

What happened

Baird kept its Outperform rating on Axsome Therapeutics but cut its price target to $220 from $246, a 10.6% decrease. The new target implies 61.8% upside from the November 2 close of $136.01.

Confirmed

Global impact / market context

A lower price target means Baird still expects the stock to rise but sees less room than before. For a beginner, that signals weaker expected upside, not a sell call, since Outperform still suggests the analyst favors the shares.

Analyst inference

Axsome shares closed at $136.01 before this update. The gap between that close and the $220 target shows how much of the analyst's expected gain was trimmed, which can shape how investors judge the stock's risk and reward.

Analyst inference

What to watch

1. Watch whether other analysts change their views on Axsome after Baird's price target cut to $220 from $246. Confirmed
2. Watch for any company announcements on sales, costs, or drug pipeline progress that could justify a higher or lower target. Proposed
3. Watch whether the stock moves toward the $136.01 close as investors weigh the smaller expected upside against Baird's Outperform rating. Analyst inference

Evidence

• Original source link unavailable